NASDAQ:DRRX - DURECT Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.75 +0.01 (+1.36 %)
(As of 03/22/2019 10:01 AM ET)
Previous Close$0.7332
Today's Range$0.7277 - $0.7497
52-Week Range$0.46 - $2.55
Volume8,019 shs
Average Volume363,979 shs
Market Capitalization$121.22 million
P/E Ratio-4.68
Dividend YieldN/A
Beta2.16
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRRX
CUSIPN/A
Phone408-777-1417

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.56 million
Book Value$0.12 per share

Profitability

Net Income$-25,320,000.00
Net Margins-136.40%

Miscellaneous

Employees88
Market Cap$121.22 million
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

DURECT (NASDAQ:DRRX) Frequently Asked Questions

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) posted its quarterly earnings data on Thursday, March, 7th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The specialty pharmaceutical company earned $3.63 million during the quarter, compared to analyst estimates of $3.65 million. DURECT had a negative return on equity of 96.70% and a negative net margin of 136.40%. View DURECT's Earnings History.

When is DURECT's next earnings date?

DURECT is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for DURECT.

What price target have analysts set for DRRX?

1 analysts have issued twelve-month price objectives for DURECT's stock. Their predictions range from $3.00 to $3.00. On average, they expect DURECT's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 301.1% from the stock's current price. View Analyst Price Targets for DURECT.

What is the consensus analysts' recommendation for DURECT?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.

Has DURECT been receiving favorable news coverage?

Media headlines about DRRX stock have trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. DURECT earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the stock's share price in the next few days.

Who are some of DURECT's key competitors?

What other stocks do shareholders of DURECT own?

Who are DURECT's key executives?

DURECT's management team includes the folowing people:
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
  • Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
  • Mr. Michael H. Arenberg, Chief Financial Officer
  • Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist

Who are DURECT's major shareholders?

DURECT's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.92%), Ingalls & Snyder LLC (5.22%), Geode Capital Management LLC (1.05%), Geode Capital Management LLC (1.05%), Gagnon Securities LLC (0.79%) and Acadian Asset Management LLC (0.59%). Company insiders that own DURECT stock include James E Brown, Jon S Saxe and Michael Arenberg. View Institutional Ownership Trends for DURECT.

Which institutional investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Asymmetry Capital Management L.P., Bell Rock Capital LLC, Ingalls & Snyder LLC, BlackRock Inc., Acadian Asset Management LLC, Tocqueville Asset Management L.P. and Mackay Shields LLC. View Insider Buying and Selling for DURECT.

Which institutional investors are buying DURECT stock?

DRRX stock was purchased by a variety of institutional investors in the last quarter, including Raymond James & Associates, SG Americas Securities LLC, Prudential Financial Inc., Geode Capital Management LLC, Geode Capital Management LLC, Virtu Financial LLC and Rhumbline Advisers. Company insiders that have bought DURECT stock in the last two years include James E Brown, Jon S Saxe and Michael Arenberg. View Insider Buying and Selling for DURECT.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $0.7480.

How big of a company is DURECT?

DURECT has a market capitalization of $121.22 million and generates $18.56 million in revenue each year. The specialty pharmaceutical company earns $-25,320,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. DURECT employs 88 workers across the globe.

What is DURECT's official website?

The official website for DURECT is http://www.durect.com.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.


MarketBeat Community Rating for DURECT (NASDAQ DRRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel